Deallus

We are so proud of all our Deallus team - past, present, and future. As part of our 20th anniversary celebrations we wanted to showcase some of our alumni who, over the past 20 years, have all played a part in our journey so far.   We are delighted to profile Stephanie Newman who was with Deallus for five years as Head of HR.   Steph says of her time: “My best memory from working at Deallus was doing a secondment in the US. It was brilliant living and working in New York City and immersing myself in HR across the pond. It was also hugely valuable for my career, plus a lot of fun.   I learnt a lot during my five years with Deallus, perhaps most importantly, the value of setting aside time for quality feedback and career discussions. The importance of this was instilled in me at Deallus and has been incredibly valuable to me in my career planning and continuous development.   #alumni #secondment #feedback #growth #careerprogression #20years #celebrations #success

Our latest Deallus paper, written by Kunal Srivastava, Tech & AI Leader, is titled: Decoding the use of ChatGPT & similar LLM applications after the dust settles: Applications of AI in Pharma and life sciences industry. You can read it here: https://lnkd.in/dBnvGyRp   In the paper Kunal explores how AI and ChatGPT has transformed the way information is researched and used – and will continue to do so. However, its strengths and limitations, like any other tool, are dependent on the knowledge and expertise of the people using it. AI therefore requires a balanced approach of understanding, assessing and ensuring the right objectives are clearly understood and articulated, and follow an considered approach.   Read the paper here: https://lnkd.in/dBnvGyRp   #AI #ChatGPT #lifesciences #consulting #competitiveintelligence #experience #expertise #potential #integration #learning #businessleadership #executiveleadership

As part of our 20th anniversary celebrations we wanted to showcase some of our alumni who, over the past 20 years, have all played a part in our journey so far. We are very proud of all our Deallus team - past, present and future.   We are delighted to profile Ines H. who was with Deallus for six years being promoted from Associate to Principal (Partner). Ines says of her time: “What made Deallus special was the entrepreneurial and collegiate spirit that permeated everything we did. The camaraderie and teamwork are what made it a special place to work. I learnt to master the balance between achieving good results for our clients, remaining authentic leadership, and enjoying the process. I also became good at tackling any number of challenges, from facilitating complex meetings to writing legal contracts!” My advice for those starting a career at Deallus is to recognise that the company and teams thrive when every individual contributes their unique strengths. So, actively look for differences in others to help you succeed. Also, it is good to fail sometimes. It is the only way to grow.” #entrepreneurial #collegiate #teamwork #camaraderie #results #process #perspective #problemsolving

In this year’s update of the Lancet Commission on dementia, the world’s leading experts offered a message of hope. Specifically, this update added two new modifiable risk factors for dementia – vision loss and high cholesterol – bringing the total number of risk factors to 14. Importantly, the authors concluded that addressing these risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of all dementia cases, even as people live longer. In the area of Alzheimer’s disease (AD), the most prevalent form of dementia, exciting new research supports the role of metabolic dysfunction in the etiology of dementia. Just recently, it was reported that treatment with the GLP-1 agonist liraglutide may be neuroprotective against AD dementia.   Here at Deallus, neuroscience continues to be one of our leading therapeutic areas, and we are encouraged that research and progress is being made to address this devasting illness.    You can read our recent blogs around neuroscience and brain health here: https://lnkd.in/e8VPeG4M You can also read the update of the The Lancet Commission on dementia here: https://lnkd.in/dCnBkncu #dementia #neuroscience #expertise #thelancet #alzheimersdisease #research #progress

Two recent Deallus blogs – written by Anna Scott, Ph.D., Deallus Senior Principal - explore the outlook for pharma’s prospects in neuroscience and why working in this therapeutic area is more exciting than ever. Read them here: https://lnkd.in/e8VPeG4M   While there remains an ongoing need for further research, a number of scientific breakthroughs in our understanding of the brain saw an uptick in investments in early-stage neuroscience drug programs in the late 2010s, bringing hope to millions of patients and their families whose lives are impacted by brain health conditions.      Neuroscience continues to be one of Deallus’ leading therapeutic areas, both in project volume and the expertise held by our consulting staff. We’ve had the privilege of partnering with many pharma organisations over the years as they navigate the challenges and complexities of drug development and commercialisation in neuroscience.    Read our blogs to find out more here: https://lnkd.in/e8VPeG4M   #blog #neuroscience #brainhealth #inspire #brainscience #sciencebreakthrough #expertise #brainawarenessweek #worldbrainday #advancements #equality #experience #leadingtheconversation

Deallus is proud to support World Brain Day on 22nd July. This year’s theme, Brain Health and Prevention, brings awareness to preventative measures that can alleviate the burden of many neurological conditions and stresses that socioeconomic status or geographic location should not be barriers to prevention. Anna Scott, Ph.D., Deallus Senior Principal, has written a blog on developments and the ongoing need for further research. Read it here: https://lnkd.in/ezkE6jbZ   For patients diagnosed with multiple sclerosis (MS), one of the most prevalent neurological conditions worldwide, early intervention is a critical form of preventive healthcare: patients treated early in their disease course accumulate disability at a slower pace than untreated patients.   “Time is brain”, initially coined in stroke patients to emphasise the need for rapid action to prevent brain damage, is a key slogan in other neurodegenerative diseases, notably Alzheimer’s disease. Compared to MS, the clinical evidence for current DMTs in AD is far less established, but already the concept of early treatment to prevent cognitive decline is a major narrative. Despite these critical advances in treating MS, people of colour tend to fall behind when it comes to early intervention with high-efficacy DMTs.    Read more about our perspective and insights in our blog here: https://lnkd.in/ezkE6jbZ   #worldbrainday #blog #MS #alzheimers #neurology #advancements #treatment #equality #precisionmedicine #expertise #experience #leadingtheconversation

It is estimated one billion people worldwide could be suffering from various immunological disorders with an estimated 1 in 10 of us likely be impacted by one or more of the 100+ autoimmune disorders identified, including: Rheumatoid arthritis, psoriasis, lupus, IBD, diabetes T1, as well as more rare autoimmune disorders including Graves’ disease, uveitis, and sarcoidosis. . On average, autoimmune patients see four different doctors over a four-year period before a diagnosis is made. What a significant unmet need!   Therefore, here at Deallus, we’re excited to be expanding our TA focus by chartering an Immunology TA Community, led by Nancy Wang, Ph.D., Principal (London).   Deallus has completed countless projects within immunology, increasing in numbers and impact over the years, with over one hundred projects completed in the most recent past. It’s time to recognise this development, and to formalise our capabilities across development and commercialisation.   We look forward to partnering with clients – existing and new – and to continue to drive much needed innovation in this space!   For more information, get in touch: https://lnkd.in/ehBub766   #immunology #meetingunmetneeds #expertise #therapyarea #experience #autoimmune 

With ever increasing costs in new medicine R&D and commercialisation, and further pressures on pricing and market access, pharmaceutical companies need to make sure they are investing in the right opportunities to generate optimal returns.   For core strategic therapy areas, cross-functional team leaders must assess “where to play?” and “how to win?” and balance independent external perspectives with the internal realities of R&D capabilities and existing pipelines.   At Deallus, we have a tried and tested approach for evaluating the relative attractiveness of a group of assets and / or diseases: the Therapy Area Optimisation Solution. This delivers a fully pressure-tested and future-looking strategy, leveraging our deep understanding of the science underlying the main therapy areas and our heritage in competitive intelligence. It ensures alignment on the most relevant set of key parameters that assess the relative opportunity (‘should we’) and the feasibility (‘could we’). Find out more: https://lnkd.in/e-qqpGRq #RandD #opportunity #commercialisation #howtowin #couldwe #shouldwe #investingright

We are very proud of our Deallus team - past, present and future. As part of our 20th anniversary celebrations we wanted to showcase some of our alumni who, over the past 20 years, have all played a part in our journey so far.   We are delighted to profile Carolyn Ng who was with Deallus for nearly three years as a Consultant in Singapore.   Carolyn reflects that her time at Deallus: “… has pushed me to think more strategically about aspects of the Pharma business that truly move the needle. Rigorous data synthesis, strategic thinking, and having direct access and exposure to senior clientele in my early career at Deallus has also shaped my professional growth tremendously.   It is tough to pick just one favourite memory but my three-month rotation to London office was very rewarding.”   #alumni #collaboration #strategy #strategicthinking #professionalgrowth #singapore

20th June is World Kidney Cancer Day bringing much needed attention to a disease affecting hundreds of thousands of people worldwide. Read our blog here: https://lnkd.in/esEDSqrA Here at Deallus we partner with many global pharma companies working at the forefront of innovation in early detection, research, and improved treatments, as well as supporting the development of next generation therapies and the development of more accessible and effective diagnostics.   To ensure success and ultimately the greatest benefit for patients, it is paramount that companies active in this space fully understand and closely monitor the scientific, clinical, and commercial potential of emerging therapies. Specifically, competitive intelligence will be essential in helping to anticipate competitor behaviours and market shifts, enabling the development of adaptive, forward-thinking strategies. Read our blog here: https://lnkd.in/esEDSqrA   #worldkidneycancerday #oncology #innovation #improvingpatientslives #clinicaladvancements #emergingtherapies